The second wave of checkpoint inhibitors with chemotherapy for advanced non-small-cell lung cancer
Mené dans 8 pays sur 723 patients atteints d'un cancer du poumon non épidermoïde non à petites cellules de stade métastatique, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans progression et de la survie globale, et la toxicité de l'ajout de l'atézolizumab à une chimiothérapie de première ligne à base de carboplatine et de nab-paclitaxel
On the basis of Allison and Honjo's Nobel Prize works, immunotherapy has greatly changed the treatment landscape of advanced non-small-cell lung cancer. Within about 3 years, immune checkpoint blockade went from second-line to first-line therapy, from advanced to locally advanced non-small-cell lung cancer treatment, and from monotherapy to combination therapy. It has made the first-line treatment of advanced non-small-cell lung cancer a competitive battlefield of crucial importance
The Lancet Oncology , commentaire, 2018